Safety management services

Safety management begins long before the first participant enters a study and continues through active trial delivery to final reporting and close-out. At the start of a study, sponsors need clear reporting pathways, defined responsibilities and protocol language that sets out how safety will be managed. During the active phase, adverse events and safety signals need to be reviewed, processed and reported appropriately. At close-out, safety information must be properly reconciled and reflected in the final study outputs.

PHARMExcel supports this full pathway with safety management that is closely connected to the operational realities of the trial. Because our safety teams work alongside project management, regulatory, data and clinical operations colleagues, safety processes are not developed in isolation. This helps ensure that the systems put in place are scientifically and regulatorily sound, but also workable for the sites and teams involved in delivery.

One of the key principles behind PHARMExcel’s approach is that safety oversight should be proportionate to the risk profile of the study. A higher-risk early-phase trial will not require the same level of handling as a lower-risk study in a more established setting, and it would not make sense to treat them as though they do.

PHARMExcel works with sponsors to develop safety plans that reflect the nature of the investigational product, the phase of the study and the wider complexity of the project. For early-phase or more intensive studies, this often means closer case review, more frequent oversight and more detailed safety management processes. For lower-risk studies, it means maintaining compliance and participant protection without creating unnecessary operational burden. This risk-based approach helps sponsors strike the right balance between robust oversight and practical delivery.

Importantly, our safety management remit applies to both investigational medicinal products and medical devices. Although the reporting terminology and pathways may differ, the need for structured, well-governed safety oversight remains the same.

Accurate and timely processing of serious safety events is a fundamental requirement in clinical research. PHARMExcel supports the management of serious adverse events, serious adverse device events, suspected unexpected serious adverse reactions and unanticipated serious adverse device effects, helping sponsors ensure that these events are assessed, documented and reported correctly.

This includes case processing, medical review coordination and the management of expedited reporting obligations to regulatory authorities, ethics committees and investigators where required. The aim is not simply to meet reporting timelines, but to maintain a clear and defensible safety record throughout the life of the study. In complex or fast-moving trials, that discipline can make a significant difference to both compliance and participant protection.

Strong safety management starts with clear planning. PHARMExcel supports the development of safety sections within clinical trial protocols and Clinical Investigation Plans, helping sponsors define how adverse events will be handled, what escalation routes are needed and how safety review procedures should operate throughout the study.

We also support the preparation of study-specific safety management plans that set out responsibilities, communication pathways and ongoing oversight processes. These frameworks are particularly valuable because they give both sponsors and sites a clearer operational structure from the outset. When reporting lines, review processes and decision-making routes are well defined, studies tend to run more smoothly and with less uncertainty during active delivery.

In some studies, particularly those involving higher-risk investigational products or more vulnerable participant groups, independent oversight is an important part of the safety framework. PHARMExcel supports the establishment and management of independent safety monitoring committees, including Independent Data Monitoring Committees and similar review bodies where they are needed.

Our role can include setting up the committee, managing the charter, organising meetings, preparing the safety data for review and writing the associated reports. This is an area where PHARMExcel offers practical value to sponsors, because the administrative and governance demands of these committees can be considerable. When handled well, they provide clear, independent oversight of the safety profile of the trial without slowing the study unnecessarily.

Safety reporting obligations during a clinical trial are governed by strict regulatory timelines and documentation requirements. PHARMExcel supports sponsors with the expedited reporting and ongoing safety submissions required during active study conduct, including the management of annual safety reporting inputs and related updates where applicable.

Our focus is on pre-marketing pharmacovigilance within the context of the trial itself. We do not position this service as broad post-marketing pharmacovigilance. Instead, our role is to help sponsors manage the safety responsibilities that arise during clinical development in a way that is compliant, well documented and suited to the risk profile of the study.